cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Novo Nordisk presents new III data for next-gen amylin Cagrilintide–semaglutide (CagriSema) as an add-on

Chen, W., Xu, L., Zhao, L., Han, Y., Wang, X., & Hu, C

See the BPC-157 vs TB-500 comparison resources for ongoing research updates

Carefully review trial quality and endpoints before adopting

During the review, the committee will likely consider: The extensive body of published research on GHK-Cu (decades of studies) Safety data for both injectable and topical routes The clinical rationale for copper peptide therapy in anti-aging and wound healing Quality control considerations for compounding GHK-Cu formulations Public comments from patients, dermatologists, anti-aging practitioners, and pharmacies Given GHK-Cu's long history of use and substantial research base, many in the peptide therapy community are cautiously optimistic about a positive PCAC recommendation particularly for the topical route

But what's interesting is with performance based individuals, myself included, much like yourself, we're on podcasts, we're doing conferences, seminars, speaking engagements